Provention Bio (Provention Bio) Additional Paid-In Capital : $528.13 Mil(As of Dec. 2022)

View and export this data going back to 2018. Start your Free Trial

What is Provention Bio Additional Paid-In Capital?

Provention Bio's quarterly additional paid-in capital increased from Jun. 2022 ($423.24 Mil) to Sep. 2022 ($518.01 Mil) and increased from Sep. 2022 ($518.01 Mil) to Dec. 2022 ($528.13 Mil).

Provention Bio's annual additional paid-in capital increased from Dec. 2020 ($288.73 Mil) to Dec. 2021 ($402.94 Mil) and increased from Dec. 2021 ($402.94 Mil) to Dec. 2022 ($528.13 Mil).

Provention Bio Additional Paid-In Capital Historical Data

The historical data trend for Provention Bio's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Provention Bio Additional Paid-In Capital Chart

Provention Bio Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Additional Paid-In Capital

Get a 7-Day Free Trial

95.43

161.21

288.73

402.94

528.13

Provention Bio Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Additional Paid-In Capital	Get a 7-Day Free Trial															402.94	408.96	423.24	518.01	528.13

Provention Bio Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Provention Bio Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Provention Bio's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Provention Bio (Provention Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Provention Bio Inc (NAS:PRVB) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

55 Broad Street, 2nd Floor, Red Bank, NJ, USA, 07701

Website

https://www.proventionbio.com

Provention Bio Inc is a clinical-stage biopharmaceutical company. It is engaged in sourcing, developing, and commercializing novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated disease, including oncological, autoimmune, and inflammatory diseases. The company's product candidates include PRV-031, for the interception, delay, or prevention of type 1 diabetes; PRV-3279, for the potential treatment of systemic lupus erythematosus; and PRV-101.

Executives

Sessa Capital (master), L.p.	10 percent owner	888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Ashleigh Palmer	director, 10 percent owner, officer: President and CEO	PROVENTION BIO, INC., 110 OLD DRIFTWAY LANE, LEBANON NJ 08833
Francisco Leon	director, 10 percent owner, officer: Chief Scientific Officer	C/O PROVENTION BIO, INC., 110 OLD DRIFTWAY LANE, LEBANON NJ 08833
Jason Hoitt	officer: Chief Commercial Officer	C/O DOVA PHARMACEUTICALS, INC., 240 LEIGH FARM ROAD, SUITE 245, DURHAM NC 27707
Justin Vogel	officer: Chief Accounting Officer	C/O PROVENTION BIO, INC., 55 BROAD STREET, RED BANK NJ 07701
Rita Jain	director	C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Sarah O'brien	officer: Chief People Officer	C/O PROVENTION BIO, INC., 55 BROAD STREET, RED BANK NJ 07701
Sessa Capital Im, L.p.	10 percent owner	888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
John Petry	10 percent owner	888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Sessa Capital Gp, Llc	10 percent owner	888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Sessa Capital Im Gp, Llc	10 percent owner	888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Miyoko Christina Yi	officer: Chief Operations Officer	C/O PROVENTION BIO, INC., 55 BROAD STREET, 2ND FLOOR, RED BANK NJ 07701
Benedict Osorio	officer: Chief Quality Officer	ONE WORLD TRADE CENTER, 47TH FLOOR, SUITE J, NEW YORK NY 10007
Eleanor Ramos	officer: Chief Medical Officer & COO	ZYMOGENETICS, INC., 1201 EASTLAKE AVENUE E, SEATTLE WA 98102
Thierry Chauche	officer: Chief Financial Officer	C/O PROVENTION BIO, INC., 55 BROAD STREET, 2ND FLOOR, RED BANK NJ 07701